The Six Signals Sponsors Use to Judge Your Site

The decision is made by people with limited information

Site selection rarely comes down to one spreadsheet. A sponsor's clinical operations lead, a CRO feasibility team, and sometimes a medical monitor each form an impression of your site from a handful of signals: your feasibility responses, your performance on prior studies, what your monitor said about you, and how fast you answered their last email. Most of those signals are things you control.

Here is what tends to matter most, in roughly the order sponsors weigh it.

1. Evidence you can find the patients

Everyone claims access to the population. Sponsors have learned to discount claims and look for mechanics. They want to know where the patients come from, not just how many exist.

Specifics that land well:

• Named referral relationships, with the specialty and approximate monthly volume
• Your own patient database broken out by condition and recency
• Prior campaigns you have run in this indication and what the screen-to-randomize ratio looked like
• Which of your competitors locally are running the same protocol, and honestly whether that will split the pool

Sites that volunteer the constraints are usually more credible than sites that volunteer only the upside.

2. Startup speed

Cycle time from site selection to first patient in is one of the few metrics every sponsor tracks and every sponsor can compare across sites. If your contract and budget negotiations historically take months, that shows up in the data they already have.

Things worth fixing before the next feasibility:

• Pre-negotiated master agreements or fallback language your legal reviewer has already blessed
• A standing IRB submission calendar so you know your real turnaround
• A named person who owns startup tasks and is not also carrying a full visit schedule

3. Protocol-specific capability, stated plainly

Sponsors are checking for equipment, certifications, ability to handle the visit burden, and whether your PI has relevant experience. The failure mode here is overclaiming. If you do not have a −80 freezer on site, say what your alternative is. Being caught short during a pre-study visit costs you future studies, not just this one.

4. Data quality and query behavior

Monitoring reports follow you. Query resolution time, protocol deviation patterns, and whether your deviations were disclosed proactively or discovered all feed into how a CRO describes your site internally. Sites with clean source documentation and a habit of self-reporting problems get second and third studies even when enrollment was middling.

5. Retention, not just enrollment

A site that randomizes twelve and keeps eleven through week 52 is more valuable than a site that randomizes eighteen and loses seven. Track your own retention by study and report it unprompted. Very few sites do, and it stands out.

6. Responsiveness as a proxy for everything else

Feasibility questionnaires returned late, or returned with blanks, read as a preview of how you will handle queries. Build a shared internal document with your standard answers — staffing, square footage, equipment, population counts, past performance — so a questionnaire takes an hour rather than a week.

What to do this quarter

Pick your three most recent studies and write down, for each: days from selection to first patient in, screen-to-randomize ratio, retention rate, and number of deviations. If you cannot produce those numbers quickly, that is the real gap — and closing it does more for your selection rate than any marketing.